Aquestive (AQST) CEO Daniel Barber Exercises Warrants

What Happened

Daniel Barber, President & CEO and a director of Aquestive Therapeutics (AQST), exercised a common stock purchase warrant on September 8, 2026 to acquire 91,743 shares at $0.96 per share, paying $88,073 in cash. The Form 4 shows a paired derivative entry reflecting the warrant was exercised (derivative disposed) and converted into common shares.

Key Details

• Transaction date: 2026-09-08; Form 4 filed: 2026-09-09 (timely).
• Shares acquired: 91,743 common shares at $0.96 each; total cash paid: $88,073.
• Derivative entry: 91,743 warrants were marked disposed (reflecting exercise into shares).
• Post-transaction holdings: not specified in the filing.
• Footnote: Warrants were issued June 8, 2022, became exercisable Dec 8, 2022, expire June 8, 2027, exercise price $0.96 per share.

Context

This was an exercise of a warrant (paying cash to buy shares), not an open-market purchase or sale. There is no separate sale reported of the newly acquired shares in this filing (i.e., not a cashless exercise followed by immediate resale). As a routine exercise by an executive, it records a purchase of company stock but does not, by itself, indicate future company performance.